Search

Displaying results 2641 - 2650 of 10000 in total
  1. Drug

    Diiodohydroxyquinoline

    go.drugbank.com/drugs/DB09115
    Approved

    Diiodohydroxyquinoline, also known as uidoquinol and iodoquinol, is a quinoline derivative that can be used in the treatment of amoebiasis. The exact mechanism of action is unknown. Iodoquinol is not currently available in any FDA-approv...

    Mixtures: NORECIL 600, FLAGENASE 400
  2. Drug

    Influenza A virus A/Kansas/14/2017 X-327 (H3N2) antigen (UV, formaldehyde inactivated)

    go.drugbank.com/drugs/DB15520
    ApprovedWithdrawn

    A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposin...

    Mixtures: Flulaval Quadrivalent 2019/2020, Flulaval Quadrivalent 2019/2020
  3. Drug

    Serdexmethylphenidate

    go.drugbank.com/drugs/DB16629
    Approved

    [L32298, L32323] Serdexmethylphenidate was granted FDA approval on March 2, 2021, and is currently marketed as a combination capsule with [dexmethylphenidate] under the trademark AZSTARYS™ by KemPharm

  4. Drug

    MK-0736

    go.drugbank.com/drugs/DB15209
    Investigational

    MK-0736 is under investigation in clinical trial NCT00679055 (A Study of How MK-0736 Affects Arterial Plaque (0736-006)(TERMINATED)).

  5. Drug

    Benzoic acid

    go.drugbank.com/drugs/DB03793
    ApprovedInvestigational

    Total Positive and Negative Syndrome Scale scores dropped by 21% compared to placebo.

    Mixtures: SKINOREN %20 KREM, 30 G, ARTU 100 ML SURUP
  6. Drug

    Calcium lactate gluconate

    go.drugbank.com/drugs/DB13365
    Investigational

    Mixtures: CALCIUM SANDOZ FORTE 300 MG/2940 MG EFERVESAN TABLET, 20 ADET, CALCIUM SANDOZ FORTE 300 MG/2940 MG EFERVESAN TABLET, 10 ADET
  7. Drug

    Pegsunercept

    go.drugbank.com/drugs/DB06611
    Investigational

    Phase II clinical trials were completed in January 2010.

  8. Drug

    Tebentafusp

    go.drugbank.com/drugs/DB15283
    ApprovedInvestigational

    Tebentafusp is a gp100 peptide-HLA-directed CD3 T cell engager. It is a bispecific, fusion protein and first-in-class drug of immune-mobilizing monoclonal T cell receptors against cancer (ImmTACs), a recently developed cancer immunothera...

  9. Drug

    Omaveloxolone

    go.drugbank.com/drugs/DB12513
    ApprovedInvestigational

    [L45424] The EMA approved this drug the following year, in February 2024, and Health Canada in March 2025 for the same condition.

  10. Drug

    Oteracil

    go.drugbank.com/drugs/DB03209
    ApprovedInvestigational

    Approved by the European Medicines Agency (EMA) in March 2011, Oteracil is available in combination with [DB09257] and [DB09256] within the commercially available product "Teysuno".

    Mixtures: TS-ONE CAPSULE 20, TS-ONE CAPSULE 20